San Diego-based Optimer Pharmaceuticals, the developer of an antibiotic for a dangerous hospital infection, said today it has raised $51.5 million through a secondary stock offering after deducting expenses. The company (NASDAQ: [[ticker:OPTR]]) sold about 4.9 million shares of common stock at $11 a share. Jefferies & Co. was the sole book-running manager in the offering. Last month, Optimer said its fidaxomicin drug candidate passed its second pivotal test against C.difficile bacterial infections, and that it plans to apply for FDA approval of the drug in the second half of 2010.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
